.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Perspectives on Systemic Therapy for Breast Cancer

EP. 1: MONALEESA-7 Trial in Premenopausal HR+ Breast Cancer

February 17th 2018

EP. 2: Quality of Life for Women with HR-Positive Breast Cancer

February 17th 2018

EP. 3: Abemaciclib for HR-Positive Metastatic Breast Cancer

February 17th 2018

EP. 4: The Role of Fulvestrant in HR+ Breast Cancer

February 17th 2018

EP. 5: Neoadjuvant Therapy for HR+ Breast Cancer

February 17th 2018

EP. 6: Ovarian Suppression in Metastatic HR+ Breast Cancer

February 17th 2018

EP. 7: Refining Neoadjuvant Chemotherapy for HER2+ Breast Cancer

February 17th 2018

EP. 8: Adjuvant Therapy for HER2+ Breast Cancer

February 17th 2018

EP. 9: HER2-Targeted Therapy for HER2 Low-Expressing Breast Cancer

February 17th 2018

EP. 10: Trastuzumab Deruxtecan for HER2+ Breast Cancer

February 17th 2018

EP. 11: Advantages with Nab-Paclitaxel in TNBC

February 17th 2018

EP. 12: PARP Inhibitors for BRCA-Mutated TNBC

February 17th 2018

EP. 13: Immunotherapy for Triple-Negative Breast Cancer

February 17th 2018

EP. 14: Take-Home Messages on Breast Oncology Advances

February 17th 2018